Study Links Z-Pak To Cardiovascular Death Risk

Last Updated on June 26, 2017

Investigation Complete

Comments |

At A Glance

This Alert Affects
Patients who took antibiotic Z-Pak, also known as Zithromax and azithromycin.
Compared to patients taking no antibacterial drug or an alternative antibiotic, patients taking Z-Pak have a slightly increased risk of suffering a cardiovascular death, according to a study in the New England Journal of Medicine.
Additional Details
Z-Pak belongs to a class of drugs known as macrolides. This class of antibacterial drugs has been linked to cardiovascular effects, specifically prolongation of the QT interval which can lead to an abnormal and sometimes-fatal heart rhythm.
On May 17, 2012, the FDA notified healthcare professionals of a study published in the New England Journal of Medicine which reported a small increase in cardiovascular deaths in patients treated with a 5-day azithromycin compared to those taking another antibiotic or no antibacterial drug at all.